Last reviewed · How we verify
Caspofungin Acetate for Injection
At a glance
| Generic name | Caspofungin Acetate for Injection |
|---|---|
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PK/PD of Caspofungin in Children Severe Infection
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
- A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis (PHASE2)
- Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
- Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (PHASE3)
- An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
- Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |